Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The integration of artificial intelligence (AI) in digital mammography (DM) screening holds promise for early breast cancer detection, potentially enhancing accuracy and efficiency. However, AI performance is not identical to that of human observers. We aimed to identify common morphological image characteristics of true cancers that are missed by either AI or human screening when their interpretations are discrepant. Twenty-six breast cancer-positive cases, identified from a large retrospective multi-institutional digital mammography dataset based on discrepant AI and human interpretations, were included in a reader study. Ground truth was confirmed by histopathology or ≥1-year follow-up. Fourteen radiologists assessed lesion visibility, morphological features, and likelihood of malignancy. AI performance was evaluated using receiver operating characteristic (ROC) analysis and area under the curve (AUC). The reader study results were analyzed using interobserver agreement measures and descriptive statistics. AI demonstrated high discriminative capability in the full dataset, with AUCs ranging from 0.903 (95% CI: 0.862-0.944) to 0.946 (95% CI: 0.896-0.996). Cancers missed by AI had a significantly smaller median size (9.0 mm, IQR 6.5-12.0) compared to those missed by human readers (21.0 mm, IQR 10.5-41.0) ( = 0.0014). Cancers in discrepant cases were often described as having 'low visibility', 'indistinct margins', or 'irregular shape'. Calcifications were observed in 27% of human-missed cancers (42/154) versus 18% of AI-missed cancers (38/210). A very high likelihood of malignancy was assigned in 32.5% (50/154) of human-missed cancers compared to 19.5% (41/210) of AI-missed cancers. Overall inter-rater agreement was poor to fair (<0.40), indicating interpretation challenges of the selected images. Among the human-missed cancers, calcifications were more frequent (42/154; 27%) than among the AI-missed cancers (38/210; 18%) ( = 0.396). Furthermore, 50/154 (32.5%) human-missed cancers were deemed to have a very high likelihood of malignancy, compared to 41/210 (19.5%) AI-missed cancers ( = 0.8). Overall inter-rater agreement on the items assessed during the reader study was poor to fair (<0.40), suggesting that interpretation of the selected images was challenging. Lesions missed by AI were smaller and less often calcified than cancers missed by human readers. Cancers missed by AI tended to show lower levels of suspicion than those missed by human readers. While definitive conclusions are premature, the findings highlight the complementary roles of AI and human readers in mammographic interpretation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191860PMC
http://dx.doi.org/10.3390/diagnostics15121566DOI Listing

Publication Analysis

Top Keywords

digital mammography
12
human readers
8
mammography screening
8
cancers missed
8
missed human
8
reader study
8
likelihood malignancy
8
human-missed cancers
8
ai-missed cancers
8
cancers
7

Similar Publications

The 2019 novel coronavirus disease (COVID-19) has brought to the forefront racial disparities in health outcomes across the US, but there is limited formal analysis into factors associated with these disparities. In-depth examination of COVID-19 disparities has been challenging due to inconsistent case definition, isolation procedures, and incomplete racial and medical information. As of June 2020, over 14,000 (25%) confirmed COVID-19 cases in Georgia did not have racial information.

View Article and Find Full Text PDF

Background: In contrast-enhanced digital mammography (CEDM) and contrast-enhanced digital breast tomosynthesis (CEDBT), low-energy (LE) and high-energy (HE) images are acquired after injection of iodine contrast agent. Weighted subtraction is then applied to generate dual-energy (DE) images, where normal breast tissues are suppressed, leaving iodinated objects enhanced. Currently, clinical systems employ a dual-shot (DS) method, where LE and HE images are acquired with two separate exposures.

View Article and Find Full Text PDF

The role of AI for improved management of breast cancer: Enhanced diagnosis and health disparity mitigation.

Comput Methods Programs Biomed

September 2025

Electrical and Computer Engineering Department, School of Engineering, Morgan State University, Baltimore, MD, 21251, USA. Electronic address:

Breast Cancer (BC) remains a leading cause of morbidity and mortality among women globally, accounting for 30% of all new cancer cases (with approximately 44,000 women dying), according to recent American Cancer Society reports. Therefore, accurate BC screening, diagnosis, and classification are crucial for timely interventions and improved patient outcomes. The main goal of this paper is to provide a comprehensive review of the latest advancements in BC detection, focusing on diagnostic BC imaging, Artificial Intelligence (AI) driven analysis, and health disparity considerations.

View Article and Find Full Text PDF

Background And Objective: The early detection of breast cancer plays a critical role in improving survival rates and facilitating precise medical interventions. Therefore, the automated identification of breast abnormalities becomes paramount, significantly enhancing the prospects of successful treatment outcomes. To address this imperative, our research leverages multiple modalities such as MRI, CT, and mammography to detect and screen for breast cancer.

View Article and Find Full Text PDF

ObjectiveTo study the implications of implementing artificial intelligence (AI) as a decision support tool in the Norwegian breast cancer screening program concerning cost-effectiveness and time savings for radiologists.MethodsIn a decision tree model using recent data from AI vendors and the Cancer Registry of Norway, and assuming equal effectiveness of radiologists plus AI compared to standard practice, we simulated costs, effects and radiologist person-years over the next 20 years under different scenarios: 1) Assuming a €1 additional running cost of AI instead of the €3 assumed in the base case, 2) varying the AI-score thresholds for single vs. double readings, 3) varying the consensus and recall rates, and 4) reductions in the interval cancer rate compared to standard practice.

View Article and Find Full Text PDF